BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Bispecific CD3xCD30 antibody exhibits potent tumor cell killing activities in CD30+ malignancies
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Bispecific CD3xCD30 antibody exhibits potent tumor cell killing activities in CD30+ malignancies
Jan. 10, 2023
No Comments
The advent of bispecific antibodies bridging two different cell types has enabled a new level of cell specificity in cancer biology that has only recently begun to be realized in the clinic.
BioWorld Science
Conferences
Cancer
Bispecific antibody
Immuno-oncology